HC Wainwright Issues Positive Forecast for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Harrow in a report released on Thursday, March 19th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.21 for the quarter, up from their previous estimate of $0.20. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s FY2026 earnings at $0.56 EPS.

HROW has been the subject of several other reports. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. Nomura lowered Harrow to a “neutral” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Cantor Fitzgerald cut their target price on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, BTIG Research reiterated a “buy” rating and issued a $63.00 target price on shares of Harrow in a research note on Wednesday, March 18th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Harrow presently has an average rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Stock Performance

Shares of HROW stock opened at $33.28 on Monday. Harrow has a 52-week low of $20.85 and a 52-week high of $54.85. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The stock has a market cap of $1.24 billion, a PE ratio of -195.75 and a beta of 0.05. The business has a 50-day simple moving average of $44.53 and a 200-day simple moving average of $43.53.

Hedge Funds Weigh In On Harrow

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Harrow by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after purchasing an additional 50,889 shares during the period. Geode Capital Management LLC grew its holdings in Harrow by 4.7% in the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock valued at $24,765,000 after purchasing an additional 36,724 shares during the period. Marshall Wace LLP increased its position in shares of Harrow by 31.5% in the second quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock valued at $17,251,000 after buying an additional 135,202 shares in the last quarter. Penn Capital Management Company LLC increased its position in shares of Harrow by 20.5% in the fourth quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after buying an additional 66,589 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Harrow by 32.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock worth $18,159,000 after buying an additional 90,331 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.